logo/base Created with Sketch.

FibroScan® Expert 630

The complete non-invasive solution for liver disease management.

Powered by LSM by VCTE, CAP and SSM by VCTE as part of an overall assessment of the liver.

Ideal point-of-care solution for high-volume hospital-based settings.


Expand clinical capabilities

The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.

Enhance exam efficiency with improved ergonomics and high-speed processing

SSM by VCTE™ is a unique, patented and validated new marker for Spleen Stiffness Measurement. 109+ peer-reviewed publications support the use of SSM by VCTE™.

LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1. 3,245 peer-reviewed publications support the use of LSM by VCTE™.

CAP™ is unique patented and validated for liver disease management. 822 international peer-reviewed publications support the use of CAP™.

User testimonial


Measurements of spleen stiffness using the FibroScan® Expert 630 equipped with the new SSM module may allow identifying esophageal varices with a high risk of bleeding. Additionally, the concomitant measurements of both hepatic and splenic stiffness can distinguish between varices caused by cirrhosis from those due to portal hypertension in the absence of cirrhosis.

Yusuf Yilmaz | Professor and MD. Gastroenterology and Hepatology - Marmara University Hospital, Istanbul, Turkey

chevron chevron

FibroScan® 630 Expert Indications for Use

The FibroScan® Expert 630 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™ ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available
with SmartExam capability.



1.European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.